Negative in Ames, in vitro chromosomal aberration and in vivo rat micronucleus assays
“Adagrasib was not mutagenic in an in vitro bacterial reverse mutation (Ames) assay and was not genotoxic in an in vitro chromosomal aberration assay or an in vivo micronucleus assay in rats.”
“Dedicated carcinogenicity studies were not conducted with adagrasib, as they are not needed to support the use of a drug intended to treat patients with advanced cancer.”
✓ VerifiedFDA multi-discipline review, p. 43Source ↗
Reproductive & developmental
No fertility, early embryonic or PPND studies (ICH S9); rat and rabbit EFD conducted
“DRF and definitive EFD studies were performed in Wistar rat and NZW rabbits. No fertility, early embryonic development or PPND studies were performed. This is considered acceptable as adagrasib is intended for treatment of advanced cancer, and the ICH S9 guideline applies.”
hERG IC50 3.8 uM, about 48-fold above human free Cmax
“Adagrasib inhibited hERG potassium channel currents with an IC50 of 3.8 μM in a safety pharmacology assessment, which is approximately 48-fold higher than the human free steady-state Cmax of ~0.08 μM based on ~98% protein-binding at the recommended dose.”
✓ VerifiedFDA multi-discipline review, p. 41Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative